Cost-effectiveness of benralizumab versus mepolizumab and dupilumab in patients with severe uncontrolled eosinophilic asthma in Spain
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Asthma"
DOI: 10.1080/02770903.2022.2139718
Abstract: Abstract Objective To assess the cost-effectiveness of benralizumab (benra) vs. mepolizumab (mepo) and dupilumab (dupi) for the treatment of patients with severe uncontrolled asthma from the Spanish Health System perspective. Methods Exacerbations avoided, quality-adjusted life… read more here.
Keywords: effectiveness benralizumab; eosinophilic asthma; asthma; patients severe ... See more keywords
Cost effectiveness of benralizumab for severe, uncontrolled oral corticosteroid–dependent asthma in Sweden
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2020.1760285
Abstract: Abstract Aim: We investigated cost effectiveness of benralizumab vs. standard of care (SOC) plus oral corticosteroids (OCS) for patients with severe, eosinophilic OCS-dependent asthma in Sweden. Materials and methods: A three-state, cohort-based Markov model of… read more here.
Keywords: cost effectiveness; asthma; cost; effectiveness benralizumab ... See more keywords